US approves new antibiotic for life-threatening infections The US Food and Drug Administration (FDA) has approved the use of a new antibiotic, ceftolozane plus tazobactam (Zerbaxa), for the treatment of adults with complicated intra-abdominal infections and complicated urinary tract infections.…
Targeting disease in the developing world A new report by the Access to Medicine Index finds that pharmaceutical companies influence access to medicines in developing countries through the development of innovative and adapted products, operating equitable pricing strategies and building local capacity.…
2014: The Pharmaceutical Journal’s news in review Looking back at some of the biggest news stories from the past year. …
Helping people look younger as an aesthetics practitioner Independent prescriber and pharmacist Tejal Sangani opened her own aesthetics clinic, SaRivaa, in 2011. Here, she explains how her pharmacy background comes in handy.…
Pregnant women at risk of mental health problems need more support, says NICE Women with a history of mental health problems should receive additional support before, during and after their pregnancy, according to new NICE guidance.…
Risk of hyperglycaemia for diabetes patients using faulty insulin pensPeople with diabetes using insulin pens from a number of faulty batches manufactured by Owen Mumford are at risk of hyperglycaemia.…
Initiative seeks to protect patients from acute kidney injury If you have not yet heard of sick day rules for reducing patients’ risk of acute kidney injury (AKI), you probably will soon.…
Risk modelling study suggests aspirin’s harms outweigh benefits for younger women For most women, the long-term benefits of aspirin do not outweigh the increase in major gastrointestinal bleeding, say researchers.…
Ebola clinical trial suspended after volunteers complain of joint pains A phase I clinical trial of the fast-tracked Ebola vaccine VSV-ZEBOV has been halted in Switzerland because some trial participants developed mild joint pain.…
Pfizer offers settlement in class action over Parkinson’s drug CabaserCompany has offered to settle a class action brought by more than 150 patients in Australia who allege they were never warned about the side effects of treatment.…
